Renal Cell Carcinoma: Dose Management in IO Plus TKI Therapy

In this segment, Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss the practical considerations of dose management for IO plus TKI combinations in renal cell carcinoma. Dr. Ramalingam highlights that while these regimens can offer meaningful clinical benefit, managing tolerability is essential to ensure patients can remain on therapy long enough to achieve optimal outcomes. The conversation focuses on strategies for balancing dose intensity with the need to address treatment-related adverse events, including timely dose modifications and supportive care interventions. Dr. Ramalingam emphasizes that maintaining patients on therapy, even with adjusted dosing, can be more beneficial than discontinuation due to toxicity. The discussion also underscores the importance of close monitoring and proactive management to support adherence and maximize treatment benefit. This segment reinforces the role of individualized dose management in optimizing outcomes in renal cell carcinoma.